An emerging focus of biomedical research in the postgenomic era has been the realization that a true understanding of the recent advances in molecular and cellular biological research requires that these advances be placed in the appropriate physiological context of organ systems and intact animals. The science of pharmacology, through its multidisciplinary approach in interrogating the reciprocal interactions of chemicals on biological systems, has traditionally embraced this challenge. The Journal of Pharmacology and Experimental Therapeutics (JPET), since its inception in 1909 by John J. Abel, has played a key role in this endeavor by providing authors a forum for the communication of state-of-the-art research on all aspects of pharmacology and its application to the improvement of human health.
During his tenure as JPET Editor, Rick Schnellmann, along with the JPET Editorial Board and staff, has worked to ensure that the journal continued its tradition of publishing only the highest quality pharmacological research. The acceptance rate over this period has decreased from 41% in 2004 to 37.5% in 2009. These efforts have resulted in an increase in the journal's impact factor to 4.31, which is near its all time high. One indicator of the vibrancy of JPET is that, in 2009, JPET articles received over 100,000 online hits per month while the online hits for JPET abstracts had increased to approximately 160,000 per month. It is noteworthy that the JPET Editorial Board has maintained its policy of providing authors with rigorous and constructive feedback on manuscripts in a timely fashion. Thus, JPET continues to be a source for scientific excellence in pharmacological research and is well positioned to enable further advances in our field. On a personal level, Rick has been an engaging and effective Editor, mentor, and colleague who has successfully enhanced the scientific impact of the journal.
In future, the new and returning Associate Editors and I will work to further enhance the role of JPET as the venue of choice for publishing innovative pharmacological research. Building on traditional areas of strength for the journal (e.g. neuropharmacology and cardiovascular pharmacology), we will work to increase submissions in under-represented areas such as those associated with aging populations. These areas include Alzheimer's disease, arthritis, cancer and chemotherapy, diabetes and metabolic disorders, and ocular pharmacology. We will continue to actively encourage submissions that effectively integrate the latest molecular and cellular research strategies and techniques with appropriate systems and in vivo research.
We also intend to expand and enhance the role of reviews and perspectives in the journal. Specifically, JPET's Perspectives in Pharmacology has been well received over the last 10 years, and we plan to expand this section of the journal next year to include coordinated thematic reviews, perspectives, and original research articles that address emerging and/or controversial issues in pharmacological research. JPET has recently migrated to Web 2.0. The new website offers several user-friendly enhancements, including easier access to article abstracts from the table of contents, keyword searching, and linked reference citations. The printing of Portable Document Format (PDF) files is easier, and the Web 2.0 site can be viewed with the web browser on smartphones such as iPhone (Apple, Cupertino, CA) and some other smartphones. We also are looking into new ways to expand the reach of JPET via the American Society for Pharmacology and Experimental Therapeutics (ASPET) website, www.aspet.org.
We continually seek feedback from our colleagues on ways to improve the journal and further advance the field of pharmacology. Please feel free to contact me ator Managing Editor Jill Filler at should you have any comments or suggestions regarding the journal. The Editorial Board and I look forward to working with our authors and the JPET staff in the coming years.
- © 2010 by The American Society for Pharmacology and Experimental Therapeutics